semaglutide weight loss domain Weight-loss drug does not slow Alzheimer's disease, two clinical trials find Long-term weight loss effects of

This allows multiple withdrawals across weeks of treatment

GLP-1 Agonists (Semaglutide, Tirzepatide) These compounds have FDA-approved versions (Ozempic, Mounjaro) with extensive safety and efficacy data from large clinical trials

Slower weight loss may help reduce the severity of facial volume loss (sometimes called "Ozempic face" or "GLP-1 face"), because rapid fat loss contributes to skin laxity more than gradual loss

Being aware of the most common errors helps patients avoid unnecessary discomfort and ensures the medication works as intended

This dosage range is generally effective and safe for most individuals